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Standard therapy for glioblastoma (GBM) includes maximal surgical resection
and radiation therapy. While it is established that radiation therapy provides
the greatest survival benefit of standard treatment modalities, the impact of
the extent of surgical resection (EOR) on patient outcome remains highly con-
troversial. While some studies describe no correlation between EOR and
patient survival even up to total resection, others propose either qualitative
(partial versus subtotal versus complete resection) or quantitative EOR thresh-
olds, below which there is no correlation with survival. This work uses a
mathematical model in the form of a reaction–diffusion partial differential
equation to simulate tumor growth and treatment with radiation therapy and
surgical resection based on tumor-specific rates of diffusion and proliferation.
Simulation of 36 tumors across a wide spectrum of diffusion and proliferation
rates suggests that while partial or subtotal resections generally do not pro-
vide a survival advantage, complete resection significantly improves patient
outcomes. Furthermore, our model predicts a tumor-specific quantitative
threshold below which EOR has no effect on patient survival and demon-
strates that this threshold increases with tumor aggressiveness, particularly
with the rate of proliferation. Thus, this model may serve as an aid for deter-
mining both when surgical resection is indicated as well as the surgical mar-
gins necessary to provide clinically significant improvements in patient
survival. In addition, by assigning relative benefits to radiation and surgical
resection based on tumor invasiveness and proliferation, this model confirms
that (with the exception of the least aggressive tumors) the survival benefit
of radiation therapy exceeds that of surgical resection.
C urrent standard therapy for glioblastoma (GBM) includesmaximal surgical resection and radiation therapy with
temozolomide.(1) Yet, the impact of the extent of surgical
resection (EOR) on patient outcome remains controversial.(2–5)
Two large reviews examining the literature prior to 1990
and one later review in 1999 were unable to conclude that
there was a relationship between EOR and patient sur-
vival.(3–5) A more recent review of 28 studies by Sanai
et al.(6) spanning the period from 1990 to 2007 demonstrated
mixed results but the weight of the evidence suggested a
positive correlation between survival and EOR, particularly
with gross total resection. Essentially all of the studies
included radiation therapy, but analysis is complicated both
by non-volumetric assessment of tumor size and by the
different reporting schemes used in the papers. Most of the
papers used a three-tier scheme of biopsy, subtotal resection
and gross total resection. Of the 24 papers using non-volu-
metric analysis, 14 papers found a positive correlation
between EOR and survival. More standardization in
measurement and reporting is available in the few papers
that used volumetric analysis. However, no clear consensus
exists in this group either. For instance, Pope et al.(7) found
no significant impact of EOR on patient survival, while
Keles et al.(8) and Lacroix et al.(9) were positive studies.
Mathematical modeling of GBM treatment that incorporates
the impact of both surgery and radiation therapy may provide
further insight into the effect of standard therapy on patient
tumor burden and survival. Accurate modeling may also provide
an avenue to understanding some of the disparities that currently
exist in the literature. This paper uses the well-studied reaction–
diffusion model of GBM to investigate the combined effects of
standard radiation therapy and surgical resection on patient sur-
vival. Although there has been significant work with this model
in the published literature, including both the effect of surgical
resection,(10,11) and more recently the effect of radiation ther-
apy,(12–14) prior analysis assessing the impact of the combination
of both surgery and radiation therapy to provide a full treatment
model for GBM is limited.
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Materials and Methods
Mathematical modeling. The proliferation and infiltration of
glioblastoma (GBM) into adjacent tissues has previously been
modeled using a partial differential equation reaction–diffusion
model of tumor growth.(11,15–17) In one spatial dimension, this
model can be written as
@C
dt
¼ D @
2C
dx2
þ qcð1 c
K
Þ
where the various terms are defined as follows: c(t,x) is the
tumor cell density, in terms of cells/mm3, which is a function
of position x and time t; D(x) is the diffusion term, in mm2/
day, which models local tumor invasion of tumor cells; and
qcð1 cKÞ is a logistic tumor growth term, where q is the
tumor proliferation rate in units of (/day), governed by a tissue
tumor carrying capacity K, in units of cells/mm3.
The carrying capacity for the tissue, K, can be considered a
cell density of 105 cells per mm3.(18) The solution domain is
L = 200 mm, and we use the standard zero-flux boundary con-
ditions @c
dx
¼ 0 at x = 0 and at x = L.(12) The partial differential
equations are solved using the pdepe function in MATLAB.
The above reaction–diffusion model provides an evolution
of the tumor cell density with time, where cell density gradu-
ally increases toward the carrying capacity K and where the
tumor grows in space, with the tumor cell-density curve mov-
ing to the right (Fig. 1).
As can be seen from Figure 1, at any time point, the model
predicts a gradient of cell density, decreasing with distance
from the center of the tumor. These mathematical predictions
mirror direct histological observations of cell density gradients
in GBM.(19) The model estimates this gradient by setting cell
density thresholds for tumor visibility on both T1 post-contrast
images and FLAIR/T2 images (Fig. 2).(14)
The T1 detection threshold, used to simulate the enhancing
T1 tumor radius, is set at 0.8 K, while the T2 threshold is
0.16 K, maintaining consistency with values from prior
work.(14)
Rockne et al.(12,13) add a radiation therapy term to this equa-
tion to develop the proliferation–invasion–radiation therapy
(PIRT) version of the model:
@c
dt
¼ D @
2c
dx2
þ qcð1 c
K
Þ  RðS; cðx; tÞÞ
The PIRT model allows the modeling of a tumor’s response
to radiation therapy as the tumor both proliferates and spreads
in space, differentiating this model from other models in which
there is no motion of tumor cells. This model is also able to
take into account the behavior of tumor cells below the MR
detection threshold.
The R term quantifies the loss of tumor cells due to radiation
therapy, which is delivered in discrete doses, and is, hence,
amenable to modeling different dosing schedules. R is defined
as a function of S, the fraction of cells surviving a radiation
dose, using the well-known linear-quadratic dose-response
model: S ¼ eðadþbd2Þ, where a (in units of per Gy) and b (in
units of per Gy2) reflect type A (single ionizing event) and
type B (pairwise interaction of ionizing events) tissue damage.
Because tissues can be somewhat characterized by an a/b
ratio, and to simplify the model to a single radiation
parameter, the a/b is held fixed, as per Rockne et al.(12,13) In
this work, similar to prior works, this ratio is held at
10 Gy.(12–14) Thus, S can be written as: S ¼ ea dðx;tÞþd
2ðx;tÞ
a=b
 
.
Fig. 1. The time evolution of the cell density profile as given by the standard reaction–diffusion model of Equation (1), with
cð0; xÞ ¼ 0:8K  e0:25x2 , K = 105 cells per mm3, D (0.4 mm2/day) and q (0.04/day).
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If S is the surviving cell fraction for a given dose, then
(1  S) is the probability of cell death. In this formulation, a
can be regarded as the parameter defining radiation sensitivity.
A higher a corresponds to a decreased probability of survival.
In addition, d reflects the given radiation dose, which is a
function of both space and time, d(x,t), allowing specific radia-
tion therapy protocols to be modeled.
In the PIRT model, the effect of radiation therapy is also
cast as a function of cell density, using the same logistic for-
mulation as the tumor growth model as follows:
R ¼ ð1 SÞ  c 1 cK
 
.(13)
Hence, at locations of high cell density, when the tumor cell
proliferation is decreased according to the logistic configura-
tion, the effect of radiation therapy is likewise decreased. This
is consistent with the understanding that radiation is most
effective in regions of high mitotic activity and high cellular
turnover. Conversely, at low cell densities, the effect of radia-
tion therapy is essentially linearly related to the fraction of
cells killed. The above formulation is equivalent to the Taylor
series approximation of having the logistic term as part of the
exponent of S.
This mathematical model can be further modified by the
addition of a surgical term, G(x,t):
@c
dt
¼ D @
2c
dx2
þ qcð1 c
K
Þ  RðS; cðx; tÞÞ  Gðx; tÞ
This allows surgeries of differing radii to be simulated, and
even allows the simulation of repeat surgical resection.
Methods
The above model was used to simulate growth and treatment
of GBM. Radiation therapy was modeled as a total of
61.2 Gy/34 doses, using the University of Washington proto-
col. The first 28 doses were given in a field using the T2
tumor boundary + 2.5 cm, while the last 6 doses were given
as a more spatially limited booster field using the enhanced T1
radius + 2 cm.(12)
Surgical radii of 0, 5, 10 and 20 mm were applied across a
range of model tumors in four groups covering the combina-
tions of high and low invasiveness and proliferation
(designated as high and low D and high and low q), using
published ranges for D and q for GBM.(12,17) This is done to
mirror the heterogeneity of biologic behavior of GBM,
including the newly discovered genetic heterogeneity, with fac-
tors such as MGMT promoter status and IDH1 mutations,
which significantly affect biologic behavior.
The high D–high q group (HH) consisted of a center value
set of D = 0.2 cm2/day and q = 0.1/day. The low D–low q
group (LL) consisted of a center value set of D = 0.04 cm2/
day and q = 0.02/day. Using these values, high D– low q
(HL) and low D–high q (LH) tumors were also modeled. For
each group, nine theoretical patients were generated by taking
the combinations of D  50% and q  50%, following the
method of Woodward et al.(10) Theoretical survival curves
generated for each group using a preset survival endpoint of
enhanced T1 tumor radius of 3.5 cm were used to allow inter-
group and intra-group comparison. This lethal radius is the
same as that used in prior modeling work by Rockne et al.(13)
and Swanson et al. Survival curves were generated for no ther-
apy, radiation therapy alone (i.e. surgical radius = 0), and sur-
gical radii of 5, 10 and 20 mm, followed by radiation therapy.
A surgical radius of 5 mm is termed partial resection, a radius
of 10 mm is designated as subtotal resection, while a radius of
20 mm, which actually goes beyond the 1.5-cm enhanced
tumor margin, is termed gross total resection.
Relying on previously published estimates, including the
variation of a with tumor proliferation, an a of 0.03/Gy was
used for the low p group and an a of 0.09/Gy was used for the
high p group. The a/b ratio was held fixed at 10 Gy.(12–14,20)
Results
The results of the radiation therapy model can be displayed in
several ways. An instructive approach is to look at the cell
density in space, at given time points, such as just prior to
therapy and immediately following the conclusion of therapy
(Fig. 3).
A second way to look at the model data is tumor radius ver-
sus time plots, using the thresholding technique described
above. Figure 4 shows the radius versus time plot of a tumor
undergoing therapy when the enhanced T1 radius (T1C)
reaches 1.5 cm. As can be seen from the plots, the tumor
regrows following therapy, until the pre-set endpoint of patient
death (T1C radius of 3.5 cm).
Applying the model in this way, theoretical survival curves
can be generated for the different tumor groups (Fig. 5).
Average untreated patient survival time across all tumor
groups was found to be 7.8 months, ranging from 3.0 months
in the HH group to 14.8 in the LL group. Modeling of radia-
tion therapy alone showed a significant increase in patient sur-
vival across all tumor groups, increasing average survival time
from 7.8 to 10.1 months. This constitutes an average of a 29%
increase in patient survival time. Radiation therapy alone was
found to be most effective in the HH group, increasing average
survival time by 54%, and least effective in the LL group for
which average survival time increased by 19%. Incorporation
of surgical resection into the simulated treatment regimen
demonstrated vastly different effects depending on EOR. Gross
total resection (20 mm) increased average survival across all
tumor groups from 10.1 months with radiation alone to
12 months, showing an independent additive effect to radiation
therapy. The combination of radiation therapy and gross total
resection was found to be most effective in the HL group in
which survival time was increased by 83% as compared to
untreated tumor progression. Contrary to gross total resection,
partial (5 mm) and subtotal resection (10 mm) showed no sig-
nificant improvement in survival in any of the tumor groups.
Fig. 2. Schematic showing cell density versus distance from tumor
center, illustrating the use of cell density thresholds to delineate cal-
culated tumor radius on T1 post-contrast and T2 weighted images.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Discussion
For most cancers the extent of surgical resection would seem
likely to correlate with patient survival. However, the relation-
ship between these two variables for GBM remains controver-
sial. The spread of GBM cells beyond visible tumor margins
and the inability to perform broad resections while preserving
critical brain functions may underlie this disconnect. Indeed,
GBM recurs even after total hemispherectomy.(2) Earlier litera-
ture reviews could not reach a conclusion as to the relationship
between EOR and survival.(3–5) Interpretation of published data
is complicated by lack of standardization in both the reporting
and measurement of EOR. For example, many studies did not
use volumetric analysis for optimal measurement of EOR, and
oftentimes EOR was not confirmed by postoperative
imaging.(2,21,22)
Given these difficulties, mathematical modeling of GBM
growth and treatment accounting for both surgery and radiation
therapy might add insight beyond that provided by empirical
evidence, particularly as to whether the extent of surgical
resection adds a survival advantage to radiotherapy alone.(4)
We modeled four GBM patient groups with various combi-
nations of high and low invasiveness and proliferation in order
to account for heterogeneity of the biologic behavior of GBM.
In the aggregate, radiation therapy alone showed a significant
increase in patient survival from 7.8 to 10.1 months (29%
increase). These results, with a 2.3-month increase, are compa-
rable to published data on the effect of radiation therapy alone
in a recent trial of elderly patients, where survival was pro-
longed by 2.9 months (from 3.9 to 6.8 months).(23) The overall
survival times in that trial are shorter than the averages for our
model, potentially reflecting the more aggressive biologic
behavior of GBM thought to be associated with elderly
patients. If only high proliferation tumor cohorts in our model
are considered, the average survival time with radiation ther-
apy alone is 6.2 months, comparable to this published data.(23)
In our model, gross total resection (20 mm) further increased
overall survival from 10.1 to 12.0 months, showing an indepen-
dent additive effect to radiation therapy. However, partial and
subtotal resection showed no additional benefit. These conclu-
sions seem to match more recently published evidence showing
a significant survival advantage for gross total resection when
added to radiation therapy, in contrast to little survival advantage
achieved with partial or subtotal resection. For instance,
meta-analysis indicates that patients undergoing subtotal
resection have an average survival of 11.3 months, compared
to 14.2 months for those with gross total resection; that is, a
survival advantage of slightly less than 3 months.(6) This
association is particularly evident in papers using
volumetric analysis,(9,24–27) and correlates well with our theoreti-
cal results of 10.1 months for partial or subtotal resection and
12 months for gross total resection.
One advantage of mathematical modeling is that it may pro-
vide additional understanding of empirical data from clinical
trials. For instance, Sanai et al. found a threshold value for
EOR of 78%, below which there was no correlation with sur-
vival, but above which there was a progressive increase in sur-
vival with EOR.(25) Chaichana et al.(24) found a difference
between the <70% and >70% groups (10.5 vs 14.4 months
average survival, respectively), without graded improvement,
while Grabowski et al.(27), similar to Lacroix et al., found a
Fig. 3. (a) Cell density profile in space at two time
points: just prior to (red curve) and just after
radiation therapy (blue curve) for a model tumor
(D = 0.2, q = 0.02, a = 0.04). It is noted that
radiation therapy causes a decrease in the cell
density curve. (b) Effect on the cell density profile
of a partial (5-mm) surgical resection, followed by
radiation therapy (blue cruve).
Fig. 4. (a) T1C radius versus time plots for a model tumor (D = 0.2, q = 0.03, a = 0.04). The blue curve represents tumor growth with no ther-
apy; death occurs at 357 days. The red curve represents the changes caused by radiation therapy, with a reduction in radius during therapy, fol-
lowed by tumor rebound; death now occurs at 422 days. It is noted that the two curves overlap prior to therapy (initial blue segment). (b)
Compares radiation therapy alone (blue then red curve) to gross total surgical resection followed by radiation therapy (blue curve); death now
occurs at 468 days. It is noted that with surgery followed by radiation therapy, the model tumor disappears on T1 post-contrast images, with a
long lag time (approximately 200 days), followed by tumor recurrence.
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cutoff at 98% EOR, with average survival of 14 months for
<98% EOR and 16 months for >98% EOR. Our model may
help understanding some of these somewhat discrepant find-
ings. For instance, our model supports a threshold effect for
EOR. We found that no tumor group showed survival benefit
between 0, 5 and 10-mm radii of resection, but all groups
showed a significant improvement at 20 mm. An important
additional insight achieved with our model is that the threshold
value above which EOR correlates with survival could be
highly dependent on tumor aggressiveness, and, in particular,
on the proliferation rate q. For example, in our model a highly
proliferative tumor from the HH group, with D = 0.2 mm2/day
and q = 0.1/day shows no improvement in survival with a
resection radius of 15 mm. This would correlate with a 100%
resection of the enhancing tumor, because treatment in the
model begins when the T1C is 1.5 cm. There is a very mini-
mal survival advantage beginning at a resection radius of
16 mm, which increases progressively with EOR, becoming
significant at 20 mm.
Thus, our model could help explain why some papers find
no correlation between EOR and survival, even up to total
resection. Our modeling of highly proliferative tumors shows a
survival advantage only when surgical resection margins
extend beyond the enhancing tumor. In this case, baseline sur-
vival with radiation is 16.7 weeks and is not improved by
resections of 5, 10 or 15 mm. At 20 mm (i.e. resection with
margins beyond T1C), survival improves to 19.1 weeks. If
even wider resection margins are possible (e.g. a 30-mm resec-
tion radius), survival increases dramatically to 26.4 weeks.
This is because the wide resection reduces the residual cells
from which the tumor recurs. However, in a tumor with a mid-
range proliferation index (e.g. D = 0.2 mm2/day and q = 0.05/
day) a minimal discernable survival advantage (defined as
2 days) begins with a surgical resection radius of 14 mm (e.g.
at 81% of enhanced tumor volume). Therefore, the different
threshold values between the various papers examining this
relationship may correspond to chance variations in the growth
characteristics of tumors in their respective patient populations.
Thus, conclusions based on our model are that radiation
therapy alone shows a significant increase in calculated patient
survival across all tumor groups. Partial and subtotal resection
in general show no additional benefit, but gross total surgical
resection has an additional added survival benefit, which is less
than that of radiation therapy in all groups except the least
aggressive tumors. Our model predicts a definite threshold
below which EOR has no effect on patient survival and further
predicts that this threshold varies with tumor aggressiveness.
For tumors with a relatively low proliferation coefficient, there
may be progressive benefit with EOR beginning at volumes of
even less than 50%. For very highly aggressive tumors, how-
ever, only a resection with margins beyond the enhanced T1
tumor radius can prolong survival, and this benefit increases
significantly with the size of the surgical margin. For moder-
ately proliferative tumors, survival advantages begin to be
attained with resection volumes of approximately 80% of the
enhanced tumor volume.
Our model is also able to assign relative benefits to radiation
and surgical resection based upon tumor invasiveness and pro-
liferation. We found that the relative benefit of radiotherapy is
greatest in the most aggressive tumor group (high D, high q),
and that radiation therapy is least effective in the least aggres-
sive tumor group. The greatest relative benefit of radiation plus
Fig. 5. Theoretical survival curves for nine patient cohorts in the HH, HL, LH and LL tumor groups. The first curve is without therapy. The sec-
ond curve represents the improved survival with radiation therapy. Overlapped on this curve are the curves for partial and subtotal resection,
showing no added survival benefit. The last curve represents gross total resection followed by radiation therapy, showing an additional benefit
for total resection.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | August 2016 | vol. 107 | no. 8 | 1114
Original Article
Radiation Therapy and Resection of GBM www.wileyonlinelibrary.com/journal/cas
total surgical resection was in the high D–low q group (ex-
pected to have the greatest tumor infiltration beyond visible
MR boundaries, but with a relatively low proliferation rate).
It is important to put our model in context relative to similar
efforts, as several other radiation therapy models have been pro-
posed in the literature. For example, the model of Wein
et al.(28) is a continuum model that uses an expanding spherical
shell model of tumor growth with a centrally necrotic core to
estimate optimized radiation dosing schedules. This model,
although quite useful in suggesting possible optimal radiation
fractionation schedules, is only accurate for a prevascular tumor
stage, and, as stated by the authors, is not expected to fully
model actual tumor growth. Furthermore, because it only main-
tains a thin shell of viable tumor, it cannot be easily used to
model surgery. Our model is ideally adapted to simulating sur-
gery, and allows regrowth of tumor in the surgical bed, mirror-
ing actual tumor recurrence patterns. Another extensively-used
approach to modeling has been that of stochastic models, using
Monte Carlo techniques at the level of individual cells or cell
clusters. As pointed out by Dionysiou et al. in his review of
such models, most are useful only for small in vitro spheroids
or very small prevascular tumors, and cannot be used for accu-
rate modeling of large in vivo tumors.(29) Moreover, these mod-
els cannot be easily “individualized” using parameters that can
be measured for each patient. One exception is the four-dimen-
sional stochastic model proposed by Dionysiou and Stamatakos
wherein the 3-dimensional tumor lattice can be adapted to an
individual patient’s tumor as outlined on an MRI, and can also
incorporate the temporal motion of cells through the cell
cycle.(29) However, the model proposed here has the advantage
of simplicity, because it uses a continuum approach. Similar to
the model of Dionysiou and Stamatakos, it can incorporate
genetic information to adjust radiation sensitivity parameters.
Moreover, it also has the capacity of using serial MRI scans to
estimate D and p for an individual tumor, probably more critical
factors than radiation sensitivity in patient survival. It would be
interesting, in future papers, to compare the simulations of the
continuum and discrete stochastic models.
The limitations of our model and similar types of analyses
are many, and generally have to do with the simplifications
inherent in mathematical modeling. For example, in our model,
tumors are modeled as each having a uniform D and q, and
growing in a spherically symmetric fashion. Tumor
invasiveness is modeled as a diffusion process. Clearly, these
are gross simplifications. Just as clearly, tumors are not uni-
formly treated exactly when the T1C radius reaches 1.5 cm,
and patients do not uniformly die when that radius reaches
3.5 cm. However, the 3.5-cm lethal radius is consistent with
empirical data on lethal glioma diameters from which Alvord
derived a range of tumor diameters from 3.1 to 8.9 cm.(30) The
hope, therefore, is as previously stated, that a good model
“catches the essential truth behind the thing it is trying to
depict (p. 32).”(31)
Future directions seek to extend the model by incorporating
other significant variables, such as the effect of residual tumor
volume on patient survival, independent of EOR, an associa-
tion which has support in the literature.(24,27) The impact of
temozolomide could also impact our model. Although temozo-
lamide has become a standard part of glioblastoma treatment,
how to incorporate the effects of temozolamide into the model
remains unclear. Initial results by Barazzuol et al.(20) suggest
that temozolamide enhances radiation sensitivity, and that this
can be modeled as a decrease in the a/b ratio. If so, that can
be easily incorporated into the model, but, again, will require
close correlation to empirical data. It is hoped that this will be
the focus of a future project. However, it is also noted that evi-
dence suggests that temozolamide is less effective for the sub-
set of GBM with unmethylated MGMT promoter, and, thus,
the impact of excluding temozolamide from the current treat-
ment model may not adversely affect its predictive capacity
over a large class of tumors.(32)
Overall, our very preliminary results suggest that at least for
tumors with moderate proliferation indices, there is no impact
on the threshold where EOR begins to improve survival, but
that the contribution of radiation therapy in relationship to
EOR towards extending longevity becomes more predominant.
Finally, as genetic profiling of GBM becomes more precisely
correlated with phenomena such as invasiveness and prolifera-
tion, additional modifications of our model may further
improve its accuracy, achieving greater ability to tailor the
model to individual patients with further potential optimization
of treatment decisions.
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